global messaging alerts

Expert Content Library Published Articles

Published Articles

  • August 25, 2021

    Single-Dose Drug Delivery Fill-Finish Facility that is Scalable, Flexible, and able to Deliver up to 45M Units Per Month Delivered within an Accelerated Timeline of Fewer Than 7 Months
    Part 3 of Pharmaceutical Technology Post-Webinar Series

    ApiJect committed to creating emergency temporary fill-finish capacity for up to 45M doses a month of a candidate COVID-19 vaccine on BFS lines by the end of 2020. All of these BFS-packaged doses could then be used, if necessary, in ApiJect Prefilled Injectors for scalable, single-dose delivery.

  • August 24, 2021

    Solving Drug Challenges with Innovation, BFS, and a Technology Platform to Create Drug
    Delivery Systems
    Part 2 of Pharmaceutical Technology Post-Webinar Series

    Learn how ApiJect built its Technology Platform around BFS to create innovative drug delivery systems for the prefilled syringe market and other sterile liquid pharmaceutical delivery formats.

  • August 23, 2021

    BFS and Prefilled Syringes: A Solution for Complex Formulations
    Part 1 of Pharmaceutical Technology Post-Webinar Series

    Many countries, including the US, lack the necessary surge capacity to reliably fill-finish and deliver billions of incremental doses of injectable drugs and vaccines during bio-emergencies.

  • May 9, 2021

    Special Feature: PFS & Parenteral Manufacturing: How COVID-19 Changed the Market
    Drug Development & Delivery, Issue: May 2021

    Worldwide, the parenteral market is seeing greater emphasis on patient safety. This is driving a strong trend to­ward unit-dose formats, including Blow-Fill-Seal pre­filled syringe, which are now the fastest-growing format for injectables.